Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, active controlled, vehicle-controlled, subject initiated study comparing efficacy and safety of ME-609 [aciclovir/hydrocortisone; Lipsovir; Medivir AB] versus acyclovir cream for treatment of recurrent Herpes simplex labialis.

Next Previous
X
Search
Trial Profile

A randomized, double-blind, active controlled, vehicle-controlled, subject initiated study comparing efficacy and safety of ME-609 [aciclovir/hydrocortisone; Lipsovir; Medivir AB] versus acyclovir cream for treatment of recurrent Herpes simplex labialis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aciclovir/hydrocortisone (Primary) ; Aciclovir
  • Indications Herpes labialis; Oral ulcer
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 17 Jan 2011 Primary endpoint 'Disease-recurrence' has been met
    • 17 Jan 2011 Primary endpoint 'Recurrence-of-infection' has been met
    • 14 Sep 2009 Results were presented at the 49th ACAAC meeting in San Francisco, California, USA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top